A proposed model for economic evaluations of major depressive disorder

European Journal of Health Economics

Volumn 13, Issue 4, 2012, Pages 501-510

  Afzali, Hossein Haji Ali ^a   Karnon, Jonathan ^a   Gray, Jodi ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Decision modelling; Depression; Discrete event simulation; Economic evaluation

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MAJOR DEPRESSION; MODEL; PRIORITY JOURNAL; SIMULATION;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEPRESSIVE DISORDER, MAJOR; HEALTH SERVICES; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; RESEARCH DESIGN;

EID: 84865604615     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-011-0321-3     Document Type: Article

References (70)

1. Ostin, T.B., Ayuso-Mateos, J.L., Mathers, C., et al.: Global burden of depressive disorders in the year 2000. Br. J. Psychiatry 184, 386-392 (2004) (Pubitemid 38624764)
2. World Health Organisation: The World Health Report 2001. Mental Health: New Understanding New Hope. WHO, Geneva (2002)
3. Guzzetta, F., Tondo, L., Centorrino, F., et al.: Lithium treatment reduces suicide risk in recurrent major depressive disorder. J. Clin. Psychiatry 68, 380-383 (2007) (Pubitemid 46506801)
4. Dumais, A., Lesage, A.D., Alda, M., Rouleau, G., Dumont, M., Chawky, N., Roy, M., Mann, J.J., Benkelfat, C., Turecki, G.: Risk factors for suicide completion in major depression: A case-control study of impulsive and aggressive behaviors in men. Am. J. Psychiatry 162, 2116-2124 (2005) (Pubitemid 41598266)
5. Wells, K.B., Stewart, A., Hays, R.D., Burnam, M.A., Rogers, W., Daniels, M., Berry, S., Greenfield, S., Ware, J.: The functioning and well-being of depressed patients. Results from the medical outcomes study. JAMA 262, 914-919 (1989)
6. Lustman, P.J., Anderson, R.J., Freedland, K.E., et al.: Depression and poor glycemic control: A meta-analytic review of the literature. Diabetes Care 23, 934-942 (2000) (Pubitemid 30480020)
7. Henry, J.A., Rivas, C.A.: Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment. Pharmacoeconomics 11, 419-443 (1997) (Pubitemid 27240271)
8. Kaplan, W., Laing, R.: Priority Medicines for Europe and the World. WHO, Geneva (2004)
9. Pharmaceutical benefits advisory committee: Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee. Pharmaceutical Benefits Advisory Committee, Canberra (2008)
10. Buxton, M.J., Drummond, M.F., Van Hout, B.A., et al.: Modelling in economic evaluation: An avoidable fact of life. Health Econ. 6, 217-227 (1997) (Pubitemid 27296586)
11. Campbell, H., Briggs, A., Buxton, M., et al.: The credibility of health economic models for health policy decision-making: The case of population screening for abdominal aortic aneurysm. J. Health Serv. Res. Policy 12, 11-17 (2007) (Pubitemid 46174200)
12. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment: Decision analytic modelling in the economic evaluation of health technologies: A consensus statement. Pharmacoeconomics 17, 443-444 (2000)
13. Karnon, J., Brown, J.: Selecting a decision model for economic evaluation: A case study and review. Health Care Manag. Sci. 1, 133-140 (1998) (Pubitemid 128695609)
14. Nuijten, M.J.: The selection of data sources for use in modelling studies. Phramacoeconomics 13, 305-316 (1998) (Pubitemid 28123370)
15. Sobocki, P.: Health Economics of Depression. Karolinska Institute, Stockholm (2006)
16. Hylan, T., Buesching, D.P., Tollefson, G.D.: Health economic evaluations of antidepressants: A review. Depress Anxiety 7, 53-64 (1998) (Pubitemid 28235114)
17. Jones, M.T., Cockrum, P.C.: A critical review of published economic modelling studies in depression. Pharmacoeconomics 17, 555-583 (2000) (Pubitemid 30407881)
18. Frank, L., Revicki, D.A., Sorensen, S.V., et al.: The economics of selective serotonin reuptake inhibitors in depression: A critical review. CNS Drugs 15, 59-83 (2001) (Pubitemid 32128491)
19. Iqbal, S.U., Prashker, M.: Pharmacoeconomic evaluation of antidepressants. A critical appraisal of methods. Pharmacoeconomics 23, 595-606 (2005) (Pubitemid 40994127)
20. Haji Ali Afzali, H., Karnon, J., Gray, J.: A critical review of model-based economic studies of depression: Modelling techniques, model structure and data sources. Pharmacoeconomics (In press
21. Harris, A., Buxton, M., O'Brien, B., et al.: Using economic evidence in reimbursement decisions for heath technologies: Experience of 4 countries. Expert Rev Pharmacoecon Outcomes Res 1, 7-12 (2001) (Pubitemid 34649740)
22. Nordstrom, G., Despiegel, N., Marteau, F., et al.: Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. J. Med. Econ. 13, 516-526 (2010)
23. Sado, M., Knapp, M., Yamauchi, K., et al.: Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Aust. N. Z. J. Psychiatry 43, 539-547 (2009)
24. Simon, J., Pilling, S., Burbeck, R., et al.: Treatment options in moderate and severe depression: Decision analysis supporting a clinical guideline. Br. J. Psychiatry 189, 494-501 (2006) (Pubitemid 44876867)
25. Sullivan, P.W., Valuck, R., Saseen, J., et al.: A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 18, 911-932 (2004) (Pubitemid 39612019)
26. François, C., Sintonen, H., Toumi, M.: Introduction of escitalopram, a new SSRI in Finland: Comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J. Med. Econ. 5, 91-107 (2002) (Pubitemid 37168799)
27. Lenox-Smith, A., Greenstreet, L., Burslem, K., et al.: Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. Clin. Drug Investig. 29, 173-184 (2009)
28. Trivedi, M.H., Wan, G.J., Mallick, R., et al.: Cost and effectiveness of venlafaxine extended-release and SSRIs in the acute phase of outpatient's treatment for major depressive disorder. J. Clin. Psychopharmacol. 24, 497-506 (2004)
29. Armstrong, E.P., Skrepnek, G.H., Haim Erder, M.: Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr. Med. Res. Opin. 23, 251-258 (2007) (Pubitemid 46333372)
30. Benedict, A., Arellano, J., De Cock, E., et al.: Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J. Affect. Disord. 120, 94-104 (2010)
31. Armstrong, E.P., Malone, D.C., Haim Erder, M.: A Markov costutility analysis of escitalopram and duloxetine for the treatment of major depressive disorder. Curr. Med. Res. Opin. 24, 1115-1121 (2008) (Pubitemid 351579169)
32. Wang, P.S., Patrick, A., Azocar, F., et al.: The costs and benefits of enhanced depression care to employers. Arch. Gen. Psychiatry 63, 1345-1353 (2006)
33. Aziz, M., Mehringer, A.M., Mozurkewich, E., et al.: Cost-utility of 2 maintenance treatments for older adults with depression who responded to a course of electroconvulsive therapy: Results from a decision analytic model. Can. J. Psychiatry 50, 389-397 (2005) (Pubitemid 43161809)
34. Sobocki, P., Ekman, M., Ovanfors, A., et al.: The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. Int. J. Clin. Pract. 62, 623-632 (2008)
35. Sobocki, P., Ekman, M., Agren, H., et al.: Model to assess the cost-effectiveness of new treatments for depression. Int J Technol Assess Health Care 22, 469-477 (2006) (Pubitemid 44622967)
36. Kupfer, D.J.: Long-term treatment of depression. J. Clin. Psychiatry 52, 28-34 (1991)
37. American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder. Am. J. Psychiatry 157, 1-45 (2000)
38. National Institute for Health and Clinical Excellence: Depression: The treatment and management of depression in adults. National Institute for Health and Clinical Excellence (2009)
39. Miller, I.W., Keitner, G.I., Schatzberg, A.F., et al.: The treatment of chronic depression: Psychosocial functioning before and after treatment with sertraline or imipramine. J. Clin. Psychiatry 59, 608-619 (1998) (Pubitemid 28555422)
40. Klein, D.N., Shankman, S.A., Rose, S.: Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am. J. Psychiatry 163, 872-880 (2006) (Pubitemid 44464536)
41. Satyanarayana, S., Enns, M.W., Cox, B.J., et al.: Prevalence and correlates of chronic depression in the Canadian community health survey: Mental health and well-being. Can. J. Psychiatry 54, 389-398 (2009)
42. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington D.C (1994)
43. Klein, D.N.: Chronic depression: Diagnosis and classification. Curr. Dir. Psychol. Sci. 19, 96-100 (2010)
44. Rowe, S.K., Rapaport, M.H.: Classification and treatment of subthreshold depression. Curr. Opin. Psychiatry 19, 9-13 (2006)
45. Keller, M.B., Kleman, G.L., Lavori, P.W., et al.: Long-term outcome of episodes of major depression. JAMA 252, 788-792 (1998)
46. McCullough, J.P., Kornstein, S.G., McCullough, P., et al.: Differential diagnosis of chronic depressive disorders. Psychiatr. Clin. North Am. 19, 55-71 (1996)
47. Fineberg, H.V.: Decision trees: Construction, uses, and limits. Bull. Cancer 67, 395-404 (1980) (Pubitemid 11181444)
48. Klein, R.W., Dittus, R.S., Roberts, S.D., et al.: Simulation modelling and health care decision making. Med. Decis. Making 13, 347-354 (1993)
49. Hardeveld, F., Spijker, J., De Graaf, R., et al.: Prevalence and predicators of recurrence of major depressive disorder in the adult population. Acta Psychiatr. Scand. 122, 184-191 (2010)
50. Lewinsohn, P.M., Rohde, P., Seeley, J.R., et al.: Natural course of adolescent major depressive disorder in community sample: Predicators of recurrence in young adults. Am. J. Psychiatry 157, 1584-1591 (2000)
51. Conradi, H.J., Jonge, P., Ormel, J.: Prediction of the three-year course of recurrent depression in primary care patients: Different risk factors for different outcomes. J. Affect. Disord. 105, 267-271 (2008) (Pubitemid 350236352)
52. Marcus, S.M., Young, E.A., Kerber, K.B., et al.: Gender differences in depression: Findings from the STAR D study. J. Affect. Disord. 87, 141-150 (2005) (Pubitemid 41039936)
53. Karnon, J.: Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ. 12, 837-848 (2003) (Pubitemid 37220634)
54. Le Lay, A., Despiegel, N., Francois, C., et al.: Can discrete event simulation be of use in modelling major depression? Cost Eff. Resour. Alloc. 4, 19 (2006)
55. Banks, J., Carson, J.S., Nelson, B.L., et al.: Discrete Event System Simulation, 5th edn. Prentice-Hall, New Jersey (2010)
56. Khan, A., Khan, S.R., Shankles, E.B., et al.: Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the clinical global impressions rating scale in antidepressant clinical trials. Int. Clin. Psychopharmacol. 17, 281-285 (2002) (Pubitemid 35283715)
57. Nierenberg, A., De Cecco, L.M.: Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression. J Clin Psychiatry 62, (Suppl) 5-9 (2001)
58. Frank, E., Prien, R.F., Jarrett, R.B., et al.: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch. Gen. Psychiatry 48, 851-855 (1991)
59. Zimmerman, M., Posternak, M., Chelminski, I.: Defining remission on the Montgomery-Asberg depression rating scale. J. Clin. Psychiatry 65, 163-168 (2004)
60. Geddes, J.R., Carney, S.M., Davies, C., et al.: Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. Lancet 361, 653-661 (2003) (Pubitemid 36246547)
61. Pliskin, J.S., Tell, E.J.: A dialysis need forecasting model: A retrospective evaluation. Med. Decis. Making 3, 489-500 (1983)
62. Harris, A., Bulfone, L.: Getting value for money: The Australian experience. In: Jost, T.S., (ed.) Health care Coverage Determinations: An International Comparative Study, pp. 25-56. Open University Press, Maidenhead, UK (2005)
63. Halpern, M.T., Luce, B.R., Brown, R.E., et al.: Health and economic outcomes modelling practices: A suggested framework. Value Health 1, 131-147 (1998) (Pubitemid 128499428)
64. Sculpher, M., Fenwick, E., Claxton, K.: Assessing quality in decision analytic cost-effectiveness models: A suggested framework and example of application. Pharmacoeconomics 17, 461-477 (2000) (Pubitemid 30398805)
65. Sheldon, T.A.: Problems of using modelling in the economic evaluation of health care. Health Econ. 5, 1-11 (1996)
66. UKPDS Outcomes Model. http://www.dtu.ox.ac.uk/outcomes model/. Accessed 11 April 2011)
67. Weinstein, M.C., O'Brien, B., Hornberger, J., et al.: Principles of good practice for decision analytic modelling in health-care evaluation: Report of the ISPOR task force on good research practices -modelling studies. Value Health 6, 9-17 (2003) (Pubitemid 36228345)
68. Eddy, D.M., Schlessinger, L.: Validation of the Archimedes diabetes model. Diabetes Care 26, 3102-3110 (2003) (Pubitemid 37339505)
69. Primary Care Services Improvement Project. http://www.adelaide.edu.au/ pcsip/(2009). Accessed 29 January 2011)
70. Beilby, J., Marley, J., Walker, D., et al.: Effects of changes in antibiotic prescribing on patient outcomes in a community setting: A natural experiment. Clin. Infect. Dis. 34, 55-64 (2002) (Pubitemid 33152666)